

DAFTAR PUSTAKA

1. Shenfield GM. Genetic polymorphisms, drug metabolism and drug concentrations. *Clin Biochem Rev* [Internet]. 2004;25(4):203–6. Tersedia pada:
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1934960&tool=pmcentrez&rendertype=abstract>
2. Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. *Genomics, Proteomics Bioinforma* [Internet]. 2016;14(5):298–313. Tersedia pada: <http://dx.doi.org/10.1016/j.gpb.2016.03.008>
3. Louet M, Labbé CM, Fagnen C, Aono CM, Homem-de-Mello P, Villoutreix BO, et al. Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C930. *PLoS One*. 2018;13(5):6–8.
4. Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and clinical considerations. *J Pers Med*. 2018;8(1):1–31.
5. Ma J, Yang XY, Qiao L, Liang LQ, Chen MH. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. *J Dig Dis*. 2008;9(2):79–83.
6. Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. *Pharmacogenet Genomics* [Internet]. Desember 2015;25(12):584–94. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/26340336>
7. Isvoran A, Louet M, Vladiu DL, Craciun D, Loriot M-A, Villoutreix BO, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. *Drug Discov Today* [Internet]. 2017;22(2):366–76. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/27693711>
8. Estany-Gestal A, Salgado-Barreira A, Sánchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: A systematic critical review.

- Pharmacogenet Genomics. 2011;21(7):357–64.
9. Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. 2012;12(6):462–7. Tersedia pada: <http://dx.doi.org/10.1038/tpj.2012.40>
 10. Seng KC, Gin GG, Sangkar JV, Phipps ME. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia. *Asia-Pacific J Mol Biol Biotechnol*. 2003;11(2):83–91.
 11. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. *Gastroenterology* [Internet]. Agustus 2007;133(2):465–71. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0016508507010074>
 12. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. *Br J Pharmacol* [Internet]. Januari 2004;141(2):205–8. Tersedia pada: <http://doi.wiley.com/10.1038/sj.bjp.0705623>
 13. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug – drug interactions with over-the-counter NSAIDs. 2015;1061–75.
 14. Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, et al. Guidance on the management of pain in older people. *Age Ageing*. 2013;42 Suppl 1.
 15. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? *Drugs*. 2004;64(23):2619–27.
 16. Pilotto A, Franceschi M, Leandro G, Di Mario F. NSAID and aspirin use by the elderly in general practice: Effect on gastrointestinal symptoms and therapies. *Drugs and Aging*. 2003;20(9):701–10.
 17. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. *Am J Gastroenterol* [Internet]. November 1987;82(11):1153–8. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/3499815>
 18. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in

- The Elderly. *Aging Dis* [Internet]. 2018;9(1):143. Tersedia pada: <http://www.aginganddisease.org/EN/10.14336/AD.2017.0306>
19. Tewary VK, Fortunko CM. A computationally efficient representation for propagation of elastic waves in anisotropic solids. *J Acoust Soc Am*. 1992;91(4):1888–96.
 20. Badan Penelitian dan Pengembangan Kesehatan. Laporan Riset Kesehatan Dasar. Jakarta; 2013.
 21. Dinas Kesehatan Provinsi Sumatera Barat. Profil Kesehatan Sumatera Barat 2013-2017. Padang; 2018.
 22. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang 2017. Padang; 2018.
 23. Robert Brooker. *Concepts of Genetics*. 1st ed. The McGraw-Hill. 2011. 804 hal.
 24. Rosenberg LE, Rosenberg DD. Framing the Field. In: *Human Genes and Genomes* [Internet]. Elsevier; 2012. hal. 3–8. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/B9780123852120000019>
 25. Eberhard Passarge. *color atlas of genetics*. 3rd ed. Thieme. 2007. 497 hal.
 26. Powledge TM. Genetic Basics. *Natl Institutes Heal* [Internet]. 2001;1–70. Tersedia pada: www.nigms.nih.gov
 27. Suzuki DT, Lewontin RC, Gelbart WM. *An Introduction to Genetic Analysis*. 8 ed. 2001. 706 hal.
 28. Clark WR, Grunstein M. Are We Hardwired?: The Role of Genes in Human Behavior. *Are We Hardwired?: The Role of Genes in Human Behavior*. 2010. 1–332 hal.
 29. Sandosh Padmanabhan. *Handbook of Pharmacogenomics and Stratified Medicine* [Internet]. 1st ed. Elsevier; 2014. 1118 hal. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/C20100673251>
 30. Haraksingh RR, Snyder MP. Impacts of Variation in the Human Genome on Gene Regulation. *J Mol Biol* [Internet]. November 2013;425(21):3970–7. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0022283613004476>
 31. Evans WE, McLeod HL. *Pharmacogenomics — Drug Disposition, Drug*

- Targets, and Side Effects. Wood AJJ, editor. *N Engl J Med* [Internet]. 6 Februari 2003;348(6):538–49. Tersedia pada: <http://www.nejm.org/doi/10.1056/NEJMra020526>
32. Harirforoosh S, Fleckenstein L, Mahajan P, Aruoma OI, Huang Y, Moridani M. The importance of including topics related to pharmacogenetics, pharmacogenomics, and medical genetics in the pharmacy curriculum. *Am J Pharm Educ* [Internet]. 1 Oktober 2009;73(6):114. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/19885085>
 33. Stamer UM, StÜber F. The pharmacogenetics of analgesia. *Expert Opin Pharmacother* [Internet]. 10 Oktober 2007;8(14):2235–45. Tersedia pada: <http://www.tandfonline.com/doi/full/10.1517/14656566.8.14.2235>
 34. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. *Pharmacogenetics* [Internet]. April 2002;12(3):251–63. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/11927841>
 35. PENNING-VAN BEEST FJA, KOERSELMAN J, HERINGS RMC. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. *J Thromb Haemost* [Internet]. Februari 2008;6(2):284–90. Tersedia pada: <http://doi.wiley.com/10.1111/j.1538-7836.2007.02844.x>
 36. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Fortnightly review: Adverse drug reactions. *BMJ* [Internet]. 25 April 1998;316(7140):1295–8. Tersedia pada: <http://www.bmj.com/cgi/doi/10.1136/bmj.316.7140.1295>
 37. Esume C. Pharmacogenomics of non-steroidal anti-inflammatory drug-induced gastrointestinal complications. *By*. 2016;(July).
 38. Sosa-Macías M, LLerena A. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. *Drug Metabol Drug Interact* [Internet]. 1 Januari 2013;28(4). Tersedia pada: <https://www.degruyter.com/view/j/dmdi.2013.28.issue-4/dmdi-2013-0037/dmdi-2013-0037.xml>
 39. Zi J, Liu D, Ma P, Huang H, Zhu J, Wei D, et al. Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug

- Interactions. *Drug Metab Pharmacokinet* [Internet]. 2010;25(4):343–50. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/20814155>
40. He S-M, Zhou Z-W, Li X-T, Zhou S-F. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. *Curr Med Chem* [Internet]. 2011;18(5):667–713. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/21182487>
41. Werner U. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. *Clin Pharmacol Ther* [Internet]. Agustus 2003;74(2):130–7. Tersedia pada: [http://doi.wiley.com/10.1016/S0009-9236\(03\)00120-6](http://doi.wiley.com/10.1016/S0009-9236(03)00120-6)
42. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. *Pharmacogenetics* [Internet]. April 2001;11(3):223–35. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/11337938>
43. Nabeel HB, Daniel EF. Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Medical M-H, editor. *Basic and Clinical Pharmacology*. 10th ed. New York; 2007. hal. 573–598.
44. Chen Y, Kuehl GE, Bigler J, Rimorin CF, Schwarz Y, Shen DD, et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. *Pharmacogenet Genomics* [Internet]. Agustus 2007;17(8):571–9. Tersedia pada: <https://insights.ovid.com/crossref?an=01213011-200708000-00001>
45. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics* [Internet]. Agustus 2000;10(6):511–8. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/10975605>
46. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, et al. Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State

- Disposition of Diclofenac and Celecoxib. *Clin Pharmacokinet* [Internet]. 2003;42(3):283–92. Tersedia pada: <http://link.springer.com/10.2165/00003088-200342030-00003>
47. Tracy TS, Matthew Hutzler J, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: Effect on atypical kinetic metabolism profiles. *Drug Metab Dispos*. 2002;30(4):385–90.
 48. Agúndez JA, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? *Expert Opin Drug Metab Toxicol* [Internet]. 2009;5(6):607–20. Tersedia pada: <http://www.tandfonline.com/doi/full/10.1517/17425250902970998>
 49. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. *Drug Metab Dispos*. 1998;26(3):261–6.
 50. Brunton L, Chabner B, Knollman B. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 2011. 849–874 hal.
 51. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochem Pharmacol*. 1997;54(1):33–41.
 52. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmüller J. Enantiospecific effects of cytochrome p450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clin Pharmacol Ther*. 2002;72(1):62–75.
 53. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Vol. 7, *Pharmacogenetics*. 1997. hal. 203–10.
 54. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9(*)3 allele. Vol. 9,

- Pharmacogenetics. 1999. hal. 71–80.
55. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Vol. 7, Pharmacogenetics. 1997. hal. 361–7.
56. Zhou S-F, Zhou Z-W, Yang L-P, Cai J-P. Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development. *Curr Med Chem* [Internet]. 2009;16(27):3480–675. Tersedia pada: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=0929-8673&volume=16&issue=27&spage=3480>
57. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. *Clin Pharmacol Ther*. 2004;76(1):18–26.
58. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. *Pharmacogenetics*. 2000;10(2):95–104.
59. Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. *Clin Med Res*. 2007;5(1):19–34.
60. Jordan S, White J. Non-steroidal anti-inflammatory drugs: clinical issues. *Nurs Stand* [Internet]. 21 Februari 2001;15(23):45–52. Tersedia pada: <http://rcnpublishing.com/doi/abs/10.7748/ns2001.02.15.23.45.c2986>
61. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. *Rheumatol Int* [Internet]. 23 Juni 2012;32(6):1491–502. Tersedia pada: <http://link.springer.com/10.1007/s00296-011-2263-6>
62. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease: Fig. 1. *J Lipid Res* [Internet]. April 2009;50(Supplement):S423–8. Tersedia pada: <http://www.jlr.org/lookup/doi/10.1194/jlr.R800094-JLR200>
63. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. *Expert Opin Drug Saf* [Internet]. 15 November 2009;8(6):669–81. Tersedia pada:

<http://www.tandfonline.com/doi/full/10.1517/14740330903311023>

64. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs : An Update of. *J Pharm Sci*. 2013;16(5):821–47.
65. Gosepath J, Brieger J, Gletsou E, Mann WJ. Expression and localization of cyclooxygenases (Cox-1 and Cox-2) in nasal respiratory mucosa. Does Cox-2 play a key role in the immunology of nasal polyps? *J Investig Allergol Clin Immunol* [Internet]. 2004;14(2):114–8. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/15301300>
66. Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? *J Cell Mol Med* [Internet]. September 2009;13(9b):3753–63. Tersedia pada: <http://doi.wiley.com/10.1111/j.1582-4934.2008.00430.x>
67. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. *Gastroenterology* [Internet]. Agustus 1996;111(2):445–54. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/8690211>
68. Champion GD, Graham GG. Pharmacokinetics of non-steroidal anti-inflammatory agents. *Aust N Z J Med* [Internet]. 1978;8 Suppl 1:94–100. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/365162>
69. Katzung BG, Francisco S, Akporiaye ET, Aminoff MJ, Francisco S, Basbaum AI, et al. *Basic and Clinical Pharmacology*. 10th ed. McGraw-Hill. 2006. 1179hal
70. Njoku D. Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis. *Int J Mol Sci* [Internet]. 22 April 2014;15(4):6990–7003. Tersedia pada: <http://www.mdpi.com/1422-0067/15/4/6990>
71. Gibson GG, Skett P. *Introduction to Drug Metabolism* 3rd Ed. 2001;256. Tersedia pada: <http://books.google.com/books?id=xtvqUVgzcRMC&pgis=1>
72. Ionescu C, CAIRA MR. *Drug Metabolism* [Internet]. Ionescu C, Caira MR, editor. Berlin/Heidelberg: Springer-Verlag; 2005. Tersedia pada:

<http://link.springer.com/10.1007/1-4020-4142-X>

73. Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: Clinical implications. *Eur J Clin Pharmacol*. 2013;69(7):1369–73.
74. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochem Pharmacol* [Internet]. 1 Juli 1997;54(1):33–41. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/9296349>
75. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmüller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *Br J Clin Pharmacol* [Internet]. Januari 2003;55(1):51–61. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/12534640>
76. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. *Biochim Biophys Acta - Gen Subj* [Internet]. Maret 2007;1770(3):489–94. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0304416506002959>
77. J. Larry Jameson, Anthony SF, Dennis LK, Stephen LH, Dan LL, Loscalzo J. Harrison's Principles of Internal Medicine. 20th ed. Jameson JL, Anthony SF, Dennis LK, Stephen LH, Dan LL, Loscalzo J, editor. Vol. 1, McGraw-Hill Education. 2018.
78. Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet* [Internet]. Oktober 2016;388(10055):2039–52. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0140673616003469>
79. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. *Ann Rheum Dis* [Internet]. 12 Januari 2007;66(8):1056–8. Tersedia pada: <http://ard.bmj.com/cgi/doi/10.1136/ard.2006.060368>
80. Singh JA. Challenges faced by patients in gout treatment: A qualitative study. *J Clin Rheumatol*. 2014;20(3):172–4.
81. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the

- management of gout. *Ann Rheum Dis*. 2017;76(1):29–42.
82. Walecki J. Psoriatic arthritis. *Polish J Radiol* [Internet]. 2013;78(1):7–17. Tersedia pada: <http://www.polradiol.com/index.php?/archives/article/883763>
83. Liu J-T. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. *World J Orthop* [Internet]. 2014;5(4):537. Tersedia pada: <http://www.wjgnet.com/2218-5836/full/v5/i4/537.htm>
84. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. *Ann Rheum Dis*. 2005;64(SUPPL. 2):74–8.
85. Carlson S, Rauchenstein J. Hypertrophic Osteoarthropathy. *J Am Osteopath Assoc* [Internet]. 1 Desember 2015;115(12):745. Tersedia pada: <http://jaoa.org/article.aspx?doi=10.7556/jaoa.2015.153>
86. Yap FY, Skalski MR, Patel DB, Schein AJ, White EA, Tomasian A, et al. Hypertrophic Osteoarthropathy: Clinical and Imaging Features. *RadioGraphics* [Internet]. 2017;37(1):157–95. Tersedia pada: <http://pubs.rsna.org/doi/10.1148/rg.2017160052>
87. Galuppi E, Bortoluzzi A, Govoni M, Trotta F. Hypertrophic osteoarthropathy: classification, diagnostic features, and treatment options. *Expert Opin Orphan Drugs*. 2016;4(8):831–6.
88. Colavite P, Sartori A. Septic arthritis: immunopathogenesis, experimental models and therapy. *J Venom Anim Toxins Incl Trop Dis* [Internet]. 2014;20(1):19. Tersedia pada: <http://jvat.biomedcentral.com/articles/10.1186/1678-9199-20-19>
89. Ravelli A, Martini A. Juvenile idiopathic arthritis. *Lancet* [Internet]. Maret 2007;369(9563):767–78. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0140673607603638>
90. Ravelli a, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis.1. Ravelli a, Viola S, Ruperto N, Corsi B, Ballardini G, Martini a. Correlation between conventional disease activity measures in juvenile chronic arthritis. *Ann Rheu. Ann Rheum Dis* [Internet]. 1997;56(3):197–200. Tersedia pada:

<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1752340&tool=pmcentrez&rendertype=abstract>

91. Huizinga T, Nigrovic P, Ruderman E, Schulze-Koops H. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Commentary. *Int J Adv Rheumatol*. 2011;9(2):73.
92. Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. *Rheumatol Ther* [Internet]. 2016;3(2):187–207. Tersedia pada: <http://link.springer.com/10.1007/s40744-016-0040-4>
93. Perry CB. Ankylosing spondylitis. A review. *J Fac Radiol*. 1956;7(3):149–54.
94. Majithia V, Geraci SA. Rheumatoid Arthritis: Diagnosis and Management. *Am J Med*. 2007;120(11):936–9.
95. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum*. 2010;62(9):2569–81.
96. Montellano PRO de. *Cytochrome P450 Structure, Mechanism, and Biochemistry*. 2nd ed. Montellano PRO de, editor. New York: Plenum Press; 1995.
97. González-Ponce HA, Rincón-Sánchez AR, Jaramillo-Juárez F, Moshage H. Natural dietary pigments: Potential mediators against hepatic damage induced by over-the-counter non-steroidal anti-inflammatory and analgesic drugs. *Nutrients*. 2018;10(2):1–39.
98. Shakunthala N. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome. *Expert Opin Drug Metab Toxicol* [Internet]. 30 Januari 2010;6(1):1–15. Tersedia pada: <http://www.tandfonline.com/doi/full/10.1517/17425250903329095>
99. Zhang H-F, Wang H-H, Gao N, Wei J-Y, Tian X, Zhao Y, et al.

- Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes. *J Pharmacol Exp Ther* [Internet]. 8 Juni 2016;358(1):83–93. Tersedia pada: <http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.116.233635>
100. Niwa T, Yamazaki H. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. *Curr Drug Metab* [Internet]. Oktober 2012;13(8):1145–59. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/22571484>
 101. Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. *Drug Metab Pharmacokinet* [Internet]. 2013;28(1):28–37. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/23165865>
 102. Guengerich FP. Rate-Limiting Steps in Cytochrome P450 Catalysis. *Biol Chem* [Internet]. 6 Januari 2002;383(10). Tersedia pada: <https://www.degruyter.com/view/j/bchm.2002.383.issue-10/bc.2002.175/bc.2002.175.xml>
 103. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clin Pharmacol Ther* [Internet]. September 1987;42(3):290–4. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/3621782>
 104. Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. *Eur J Clin Pharmacol* [Internet]. 1975;9(2–3):219–27. Tersedia pada: <http://link.springer.com/10.1007/BF00614021>
 105. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. *Clin Pharmacol Ther* [Internet]. Oktober 1987;42(4):388–94. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/3665337>
 106. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Bäckman M, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proc Natl Acad Sci U S A* [Internet]. 13 Oktober 1998;95(21):12208–13. Tersedia pada:

<http://www.ncbi.nlm.nih.gov/pubmed/9770465>

107. PILOTTO A, FRANCESCHI M, VITALE DF, ZANINELLI A, MASOTTI G, RENGO F. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. *Aliment Pharmacol Ther* [Internet]. Juli 2005;22(2):147–55. Tersedia pada: <http://doi.wiley.com/10.1111/j.1365-2036.2005.02537.x>
108. Ramakrishnan K, Salinas RC. Peptic ulcer disease. *Am Fam Physician* [Internet]. 1 Oktober 2007;76(7):1005–12. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/17956071>
109. Spiegel BMR, Chiou C-F, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups. *Arthritis Rheum* [Internet]. 15 April 2005;53(2):185–97. Tersedia pada: <http://doi.wiley.com/10.1002/art.21065>
110. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, et al. Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal Bleeding. *N Engl J Med* [Internet]. 21 September 2000;343(12):834–9. Tersedia pada: <http://www.nejm.org/doi/abs/10.1056/NEJM200009213431202>
111. Bruno A, Tacconelli S, Patrignani P. Variability in the response to non-steroidal anti-inflammatory drugs: Mechanisms and perspectives. *Basic Clin Pharmacol Toxicol*. 2014;114(1):56–63.
112. Shiotani A, Sakakibara T, Nomura M, Yamanaka Y, Nishi R, Imamura H, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. *J Gastroenterol Hepatol*. 2010;25(SUPPL. 1):25–8.
113. Matsui H, Shimokawa O, Kaneko T, Nagano Y, Rai K, Hyodo I. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. *J Clin Biochem Nutr* [Internet]. 2011;48(2):107–11. Tersedia pada: <http://joi.jlc.jst.go.jp/JST.JSTAGE/jcbrn/10-79?from=CrossRef>
114. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. *Gastroenterology* [Internet]. September 2000;119(3):706–14. Tersedia pada:

<http://www.ncbi.nlm.nih.gov/pubmed/10982765>

115. Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. *Gastroenterology* [Internet]. Juli 2008;135(1):41–60. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0016508508007944>
116. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. *Gastroenterology* [Internet]. Juni 1993;104(6):1832–47. Tersedia pada: <http://www.ncbi.nlm.nih.gov/pubmed/8500743>
117. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, et al. Present status and strategy of NSAIDs-induced small bowel injury. *J Gastroenterol* [Internet]. 1 September 2009;44(9):879–88. Tersedia pada: <http://link.springer.com/10.1007/s00535-009-0102-2>
118. Schmidt-Martin D, Quigley EMM. The Definition of Dyspepsia. In: *Dyspepsia in Clinical Practice* [Internet]. New York, NY: Springer New York; 2011. hal. 1–8. Tersedia pada: http://link.springer.com/10.1007/978-1-4419-1730-0_1
119. Madisch A, Andresen V, Enck P, Labenz J, Frieling T, Schemann M. The Diagnosis and Treatment of Functional Dyspepsia. *Dtsch Aerzteblatt Online* [Internet]. 30 Maret 2018;118(47):1729–32. Tersedia pada: <https://www.aerzteblatt.de/10.3238/arztebl.2018.0222>
120. Jones MP. Evaluation and treatment of dyspepsia. *Postgrad Med J*. 2003;79(927):25–9.
121. Richard TS, editor. *Encyclopedia of Race, Ethnicity, and Society*. 1st ed. London: SAGE; 2008. 1752 hal.
122. Jaber N, Oudah M, Kowatli A, Jibril J, Baig I, Mathew E, et al. Dietary and Lifestyle Factors Associated with Dyspepsia among Pre-clinical Medical Students in Ajman, United Arab Emirates. *Cent Asian J Glob Heal* [Internet]. 15 Agustus 2016;5(1). Tersedia pada: <http://cajgh.pitt.edu/ojs/index.php/cajgh/article/view/192>
123. Bertram TA, Ludlow JW, Basu J, Muthupalani S. Digestive Tract. In: *Haschek and Rousseaux's Handbook of Toxicologic Pathology* [Internet].

- Elsevier; 2013. hal. 2277–359. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/B978012415759000056X>
124. Rubach M, Lang R, Seebach E, Somoza MM, Hofmann T, Somoza V. Multi-parametric approach to identify coffee components that regulate mechanisms of gastric acid secretion. *Mol Nutr Food Res*. 2012;56(2):325–35.
 125. Di Mario F, Goni E. Gastric acid secretion: Changes during a century. *Best Pract Res Clin Gastroenterol* [Internet]. 2014;28(6):953–65. Tersedia pada: <http://dx.doi.org/10.1016/j.bpg.2014.10.006>
 126. Shimamoto T, Yamamichi N, Kodashima S, Takahashi Y, Fujishiro M, Oka M, et al. No Association of Coffee Consumption with Gastric Ulcer, Duodenal Ulcer, Reflux Esophagitis, and Non-Erosive Reflux Disease: A Cross-Sectional Study of 8,013 Healthy Subjects in Japan. Guan X-Y, editor. *PLoS One* [Internet]. 12 Juni 2013;8(6):e65996. Tersedia pada: <http://dx.plos.org/10.1371/journal.pone.0065996>
 127. Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Influence of alcohol consumption on IBS and dyspepsia. *Neurogastroenterol Motil*. 2006;18(11):1001–8.
 128. Saneei P, Sadeghi O, Feizi A, Keshteli AH, Daghighzadeh H, Esmailzadeh A, et al. Relationship between spicy food intake and chronic uninvestigated dyspepsia in Iranian adults. *J Dig Dis*. 2016;17(1):28–35.
 129. Wood AM, Brock TM, Heil K, Holmes R, Weusten A. A Review on the Management of Hip and Knee Osteoarthritis. *Int J Chronic Dis* [Internet]. 2013;2013:1–10. Tersedia pada: <http://www.hindawi.com/journals/ijcd/2013/845015/>
 130. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. *Gut* [Internet]. 1 Maret 1991;32(3):252–5. Tersedia pada: <http://gut.bmj.com/cgi/doi/10.1136/gut.32.3.252>
 131. Kellner HL, Li C, Essex MN. Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial§. *Open Rheumatol J* [Internet]. 13 November 2013;7(1):96–100. Tersedia pada:

<https://openrheumatologyjournal.com/VOLUME/7/PAGE/96/>

132. The Exome Aggregation Consortium. Variant: 10:96741053 A / C [Internet]. ExAC Broadinstitute. [dikutip 20 Juni 2019]. Tersedia pada: <http://exac.broadinstitute.org/variant/10-96741053-A-C>
133. Kavitt RT, Lipowska AM, Anyane-Yeboah A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. Am J Med [Internet]. 2019;132(4):447–56. Tersedia pada: <https://doi.org/10.1016/j.amjmed.2018.12.009>

